Clinical Trial of PCV24 in Infants Aged 2-23 Months

Summary

A Phase 1b clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 42 days)-23 months. The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV24. The trial is a randomized, double-blind, positive controlled phase Ib clinical trial.

Timeline

Start

2025-05-08

Primary completion

2026-06

Completion

2026-06

Drugs

Indications